Waxman Uses Plan B, FDA Acting Head To Spotlight Conflict-Of-Interest Bill
This article was originally published in The Tan Sheet
Executive Summary
Rep. Henry Waxman (D-Calif.) is highlighting the escalating controversy surrounding the emergency contraceptive Plan B to build support for a bill intended to limit the politicization of scientific decisions
You may also be interested in...
New Acting Commissioner Von Eschenbach Brings Capitol Hill Clout – Gottlieb
FDA Acting Commissioner Andrew von Eschenbach's "clout on the Hill" could temper the perceived weakness usually associated with acting status, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Acting FDA Head Von Eschenbach Takes A Step Back At NCI
FDA Acting Commissioner Andrew von Eschenbach's decision to step away from day-to-day management duties at the National Cancer Institute follows a week of criticism from Capitol Hill related to his dual role
Energizer Grows Personal Care With Acquisition Of Leading Sun-Care Brands
Energizer Holdings will gain Banana Boat and Hawaiian Tropic - the No. 2- and No. 4-selling sun- care brands, respectively - through its $1.9 billion purchase of Playtex Products, the companies announce July 12